Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0560661
Funder
Australian Research Council
Funding Amount
$245,300.00
Summary
Particulate Characterisation for Pharmaceutical and Engineering Applications. The aim of this proposal is to establish joint facilities between the University of Sydney, Monash University and UNSW for the characterization of surface properties and particle sizes of pharmaceutical aerosols and industrial powders. Such knowledge is important for controlling aerosol production and delivery of drug particles to the lungs. This will have a significant benefit to the pharmaceutical industry and patien ....Particulate Characterisation for Pharmaceutical and Engineering Applications. The aim of this proposal is to establish joint facilities between the University of Sydney, Monash University and UNSW for the characterization of surface properties and particle sizes of pharmaceutical aerosols and industrial powders. Such knowledge is important for controlling aerosol production and delivery of drug particles to the lungs. This will have a significant benefit to the pharmaceutical industry and patients requiring aerosol treatment. Further, the proposed facilities will enhance research in complex particulate processes and modelling, functional nanomaterials, and soft sensor development, thus keeping Australia at the forefront of powder research into various high value adding particulate areas.Read moreRead less
Discrete particle simulation of powder dispersion in pharmaceutical aerosol inhalers. A successful completion of the project will i) greatly enhance the Australian R&D profile and capabilities of both computational modelling and pharmaceutical aerosol research in the world; ii) provide an improved delivery of therapeutic dose to patients via inhalers with better performance to enhance the therapeutic benefits; iii) enable wide availability of inexpensive and effective pharmaceutical inhalation p ....Discrete particle simulation of powder dispersion in pharmaceutical aerosol inhalers. A successful completion of the project will i) greatly enhance the Australian R&D profile and capabilities of both computational modelling and pharmaceutical aerosol research in the world; ii) provide an improved delivery of therapeutic dose to patients via inhalers with better performance to enhance the therapeutic benefits; iii) enable wide availability of inexpensive and effective pharmaceutical inhalation products to the Australian community for the treatment of asthma and other diseases, iv) facilitate environmentally friendly technology since powder aerosol delivery does not require any harmful organic solvents to operate.Read moreRead less